Genetic Screening for Synthetic Lethal Partners of Polynucleotide Kinase/Phosphatase: Potential for Targeting SHP-1–Depleted Cancers
- 14 November 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (22), 5934-5944
- https://doi.org/10.1158/0008-5472.can-12-0939
Abstract
A genetic screen using a library of 6,961 siRNAs led to the identification of SHP-1 (PTPN6), a tumor suppressor frequently mutated in malignant lymphomas, leukemias, and prostate cancer, as a potential synthetic lethal partner of the DNA repair protein polynucleotide kinase/phosphatase (PNKP). After confirming the partnership with SHP-1, we observed that codepletion of PNKP and SHP-1 induced apoptosis. A T-cell lymphoma cell line that is SHP-1 deficient (Karpas 299) was shown to be sensitive to a chemical inhibitor of PNKP, but resistance was restored by expression of wild-type SHP-1 in these cells. We determined that while SHP-1 depletion does not significantly impact DNA strand-break repair, it does amplify the level of reactive oxygen species (ROS) and elevate endogenous DNA damage. The ROS scavenger WR1065 afforded protection to SHP-1–depleted cells treated with the PNKP inhibitor. We propose that codisruption of SHP-1 and PNKP leads to an increase in DNA damage that escapes repair, resulting in the accumulation of cytotoxic double-strand breaks and induction of apoptosis. This supports an alternative paradigm for synthetic lethal partnerships that could be exploited therapeutically. Cancer Res; 72(22); 5934–44. ©2012 AACR.Other Versions
This publication has 48 references indexed in Scilit:
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandingsMolecular Oncology, 2011
- Tidying up loose ends: the role of polynucleotide kinase/phosphatase in DNA strand break repairTrends in Biochemical Sciences, 2011
- Targeting DNA repair in breast cancer: A clinical and translational updateCancer Treatment Reviews, 2010
- Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break RepairClinical Cancer Research, 2009
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation CarriersThe New England Journal of Medicine, 2009
- Synthetic Lethality — A New Direction in Cancer-Drug DevelopmentThe New England Journal of Medicine, 2009
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- Rate of depurination of native deoxyribonucleic acidBiochemistry, 1972
- SYNTHETIC LETHALITY AND SEMI-LETHALITY AMONG FUNCTIONALLY RELATED MUTANTS OF DROSOPHILA MELANOGASTERGenetics, 1968